Top

Published in:

Open Access 01-12-2021 | Stroke | Research

Soluble ST2 and risk of cognitive impairment after acute ischemic stroke: a prospective observational study

Authors: Yinwei Zhu, Chongquan Fang, Qi Zhang, Yaling Lu, Rui Zhang, Aili Wang, Xiaoqing Bu, Jintao Zhang, Zhong Ju, Yonghong Zhang, Tan Xu, Chongke Zhong

Published in: BMC Geriatrics | Issue 1/2021

Abstract

Background

Soluble suppression of tumorigenesis-2 (sST2) was reported to be associated with cognitive performance and risk of incident stroke. However, the impact of sST2 on cognitive function after ischemic stroke is unclear. We aimed to assess the association of sST2 and cognitive impairment at 3 months in acute ischemic stroke patients.

Methods

Baseline plasma sST2 levels were measured in 619 ischemic stroke patients (mean age: 60.0 ± 10.5 years) from 7 participating hospitals of the China Antihypertensive Trial in Acute Ischemic Stroke. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) were used to assess cognitive status. Cognitive impairment was defined as a MoCA score < 23 or MMSE score < 27. The association between sST2 and cognitive impairment was evaluated by logistic regression analysis.

Results

325 (52.5%) or 323 (52.2%) participants developed cognitive impairment according to MoCA or MMSE. After adjustment for age, sex, education, and other covariates, the odds ratio for the highest vs lowest quartile of sST2 was 2.38 (95% CI, 1.42–4.00) and 1.82 (95% CI 1.09–3.03) risk of cognitive impairment defined by MoCA and MMSE score, respectively. Incorporation sST2 into a model containing conventional risk factors significantly improved reclassification.

Conclusions

Elevated plasma sST2 levels were significantly associated with post-stroke cognitive impairment.

Available only for authorised users

Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990-2010: findings from the global burden of disease study 2010. Lancet (London, England). 2014;383(9913):245–54.CrossRef

Tang EY, Amiesimaka O, Harrison SL, Green E, Price C, Robinson L, et al. Longitudinal effect of stroke on cognition: a systematic review. J Am Heart Assoc. 2018;7(2):e006443.CrossRef

Swartz RH, Bayley M, Lanctot KL, Murray BJ, Cayley ML, Lien K, et al. Post-stroke depression, obstructive sleep apnea, and cognitive impairment: rationale for, and barriers to, routine screening. Int J Stroke. 2016;11(5):509–18. https://doi.org/10.1177/1747493016641968.CrossRefPubMed

Mijajlovic MD, Pavlovic A, Brainin M, Heiss WD, Quinn TJ, Ihle-Hansen HB, et al. Post-stroke dementia - a comprehensive review. BMC Med. 2017;15(1):11. https://doi.org/10.1186/s12916-017-0779-7.CrossRefPubMedPubMedCentral

Kwon HS, Lee D, Lee MH, Yu S, Lim JS, Yu KH, Oh MS, Lee JS, Hong KS, Lee EJ et al. Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study. J Neurol. 2020;267(3):688-93.

van der Velpen IF, Yancy CW, Sorond FA, Sabayan B. Impaired cardiac function and cognitive brain aging. Can J Cardiol. 2017;33(12):1587–96. https://doi.org/10.1016/j.cjca.2017.07.008.CrossRefPubMed

van der Velpen IF, Feleus S, Bertens AS, Sabayan B. Hemodynamic and serum cardiac markers and risk of cognitive impairment and dementia. Alzheimers Dement. 2017;13(4):441–53. https://doi.org/10.1016/j.jalz.2016.09.004.CrossRefPubMed

Hooghiemstra AM, Leeuwis AE, Bertens AS, Biessels GJ, Bots ML, Brunner-La Rocca HP, et al. Frequent cognitive impairment in patients with disorders along the heart-brain Axis. Stroke. 2019;50(12):3369–75. https://doi.org/10.1161/STROKEAHA.119.026031.CrossRefPubMed

Eggermont LH, de Boer K, Muller M, Jaschke AC, Kamp O, Scherder EJ. Cardiac disease and cognitive impairment: a systematic review. Heart. 2012;98(18):1334–40. https://doi.org/10.1136/heartjnl-2012-301682.CrossRefPubMed

10.

Cushman M, Callas PW, McClure LA, Unverzagt FW, Howard VJ, Gillett SR, et al. N-terminal pro-B-type natriuretic peptide and risk of future cognitive impairment in the REGARDS cohort. J Alzheimers Dis. 2016;54(2):497–503. https://doi.org/10.3233/JAD-160328.CrossRefPubMed

11.

Veugen MGJ, Henry RMA, Brunner-La Rocca HP, Dagnelie PC, Schram MT, van Agtmaal MJM, et al. Cross-sectional associations between cardiac biomarkers, cognitive performance, and structural brain changes are modified by age. Arterioscler Thromb Vasc Biol. 2018;38(8):1948–58. https://doi.org/10.1161/ATVBAHA.118.311082.CrossRefPubMed

12.

Schneider AL, Rawlings AM, Sharrett AR, Alonso A, Mosley TH, Hoogeveen RC, et al. High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. Eur Heart J. 2014;35(27):1817–24. https://doi.org/10.1093/eurheartj/ehu124.CrossRefPubMedPubMedCentral

13.

Nagata T, Ohara T, Hata J, Sakata S, Furuta Y, Yoshida D, et al. NT-proBNP and risk of dementia in a general Japanese elderly population: the Hisayama study. J Am Heart Assoc. 2019;8(17):e011652. https://doi.org/10.1161/JAHA.118.011652.CrossRefPubMedPubMedCentral

14.

Andersson C, Preis SR, Beiser A, DeCarli C, Wollert KC, Wang TJ, et al. Associations of circulating growth differentiation Factor-15 and ST2 concentrations with subclinical vascular brain injury and incident stroke. Stroke. 2015;46(9):2568–75.CrossRef

15.

He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014;311(5):479–89. https://doi.org/10.1001/jama.2013.282543.CrossRefPubMed

16.

Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24(1):35–41. https://doi.org/10.1161/01.STR.24.1.35.CrossRefPubMed

17.

Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9. https://doi.org/10.1111/j.1532-5415.2005.53221.x.CrossRefPubMed

18.

Carson N, Leach L, Murphy KJ. A re-examination of Montreal cognitive assessment (MoCA) cutoff scores. Int J Geriatr Psychiatry. 2018;33(2):379–88. https://doi.org/10.1002/gps.4756.CrossRefPubMed

19.

Swartz RH, Cayley ML, Lanctot KL, Murray BJ, Smith EE, Sahlas DJ, et al. Validating a pragmatic approach to cognitive screening in stroke prevention clinics using the Montreal cognitive assessment. Stroke. 2016;47(3):807–13. https://doi.org/10.1161/STROKEAHA.115.011036.CrossRefPubMed

20.

Broersen LHA, Siegerink B, Sperber PS, von Rennenberg R, Piper SK, Nolte CH, Heuschmann PU, Endres M, Scheitz JF, Liman TG. High-Sensitivity Cardiac Troponin T and Cognitive Function in Patients With Ischemic Stroke. Stroke. 2020;51(5):1604–7.

21.

De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis: role in health and disease. Cytokine Growth Factor Rev. 2015;26(6):615–23. https://doi.org/10.1016/j.cytogfr.2015.07.017.CrossRefPubMed

22.

Matilla L, Ibarrola J, Arrieta V, Garcia-Peña A, Martinez-Martinez E, Sádaba R, et al. Soluble ST2 promotes oxidative stress and inflammation in cardiac fibroblasts: an in vitro and in vivo study in aortic stenosis. Clin Sci (London, England : 1979). 2019;133(14):1537–48.CrossRef

23.

Altara R, Ghali R, Mallat Z, Cataliotti A, Booz GW, Zouein FA. Conflicting vascular and metabolic impact of the IL-33/sST2 axis. Cardiovasc Res. 2018;114(12):1578–94. https://doi.org/10.1093/cvr/cvy166.CrossRefPubMed

24.

Dieplinger B, Bocksrucker C, Egger M, Eggers C, Haltmayer M, Mueller T. Prognostic value of inflammatory and cardiovascular biomarkers for prediction of 90-day all-cause mortality after acute ischemic stroke-results from the Linz stroke unit study. Clin Chem. 2017;63(6):1101–9. https://doi.org/10.1373/clinchem.2016.269969.CrossRefPubMed

25.

Wolcott Z, Batra A, Bevers MB, Sastre C, Khoury J, Sperling M, et al. Soluble ST2 predicts outcome and hemorrhagic transformation after acute stroke. Ann Clin Transl Neurol. 2017;4(8):553–63. https://doi.org/10.1002/acn3.435.CrossRefPubMedPubMedCentral

26.

Tian X, Guo Y, Wang X, Pei L, Wang X, Wu J, et al. Serum soluble ST2 is a potential long-term prognostic biomarker for transient Ischaemic attack and Ischaemic stroke. Eur J Neurol. 2020;27(11):2202–8. https://doi.org/10.1111/ene.14419.CrossRefPubMed

27.

Fu AK, Hung KW, Yuen MY, Zhou X, Mak DS, Chan IC, et al. IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A. 2016;113(19):E2705–13. https://doi.org/10.1073/pnas.1604032113.CrossRefPubMedPubMedCentral

28.

von Rennenberg R, Siegerink B, Ganeshan R, Villringer K, Doehner W, Audebert HJ, et al. High-sensitivity cardiac troponin T and severity of cerebral white matter lesions in patients with acute ischemic stroke. J Neurol. 2019;266(1):37–45. https://doi.org/10.1007/s00415-018-9085-3.CrossRef

29.

Yatawara C, Ng KP, Chander R, Kandiah N. Associations between lesions and domain-specific cognitive decline in poststroke dementia. Neurology. 2018;91(1):e45–54. https://doi.org/10.1212/WNL.0000000000005734.CrossRefPubMed

30.

Litak J, Mazurek M, Kulesza B, Szmygin P, Litak J, Kamieniak P, Grochowski C. Cerebral Small Vessel Disease. Int J Mol Sci. 2020;21(24):9729.

31.

Gottesman RF, Hillis AE. Predictors and assessment of cognitive dysfunction resulting from ischaemic stroke. Lancet Neurol. 2010;9(9):895–905. https://doi.org/10.1016/S1474-4422(10)70164-2.CrossRefPubMedPubMedCentral

32.

Luo Y, Zhou Y, Xiao W, Liang Z, Dai J, Weng X, et al. Interleukin-33 ameliorates ischemic brain injury in experimental stroke through promoting Th2 response and suppressing Th17 response. Brain Res. 2015;1597:86–94. https://doi.org/10.1016/j.brainres.2014.12.005.CrossRefPubMed

33.

Traxler D, Zimmermann M, Simader E, Veraar CM, Moser B, Mueller T, et al. The inflammatory markers sST2, HSP27 and hsCRP as a prognostic biomarker panel in chronic heart failure patients. Clin Chim Acta. 2020;510:507–14. https://doi.org/10.1016/j.cca.2020.07.050.CrossRefPubMed

34.

Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol. 2016;12(10):594–604. https://doi.org/10.1038/nrneurol.2016.125.CrossRefPubMed

35.

Wang A, Liu J, Meng X, Li J, Wang H, Wang Y, et al. Association between oxidized low-density lipoprotein and cognitive impairment in patients with ischemic stroke. Eur J Neurol. 2018;25(1):185–91. https://doi.org/10.1111/ene.13497.CrossRefPubMed

36.

Lande MB, Kupferman JC. Blood pressure and cognitive function in children and adolescents. Hypertension. 2019;73(3):532–40. https://doi.org/10.1161/HYPERTENSIONAHA.118.11686.CrossRefPubMedPubMedCentral

37.

Palta P, Carlson MC, Crum RM, Colantuoni E, Sharrett AR, Yasar S, et al. Diabetes and cognitive decline in older adults: the Ginkgo evaluation of memory study. J Gerontol A Biol Sci Med Sci. 2017;73(1):123–30.CrossRef

38.

Makin SD, Turpin S, Dennis MS, Wardlaw JM. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. J Neurol Neurosurg Psychiatry. 2013;84(8):893–900. https://doi.org/10.1136/jnnp-2012-303645.CrossRefPubMedPubMedCentral

39.

Krogh J, Benros ME, Jorgensen MB, Vesterager L, Elfving B, Nordentoft M. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun. 2014;35:70–6. https://doi.org/10.1016/j.bbi.2013.08.014.CrossRefPubMed

40.

Zhong C, Bu X, Xu T, Guo L, Wang X, Zhang J, et al. Serum matrix metalloproteinase-9 and cognitive impairment after acute ischemic stroke. J Am Heart Assoc. 2018;7(1):e007776.CrossRef

41.

Zhu Z, Zhong C, Guo D, Bu X, Xu T, Guo L, et al. Multiple biomarkers covering several pathways improve predictive ability for cognitive impairment among ischemic stroke patients with elevated blood pressure. Atherosclerosis. 2019;287:30–7. https://doi.org/10.1016/j.atherosclerosis.2019.05.028.CrossRefPubMed

42.

Ge J, Li R, Yuan P, Che B, Bu X, Shao H, et al. Serum tissue inhibitor of metalloproteinase-1 and risk of cognitive impairment after acute ischaemic stroke. J Cell Mol Med. 2020;24(13):7470–8. https://doi.org/10.1111/jcmm.15369.CrossRefPubMedPubMedCentral

43.

Cumming TB, Blomstrand C, Bernhardt J, Linden T. The NIH stroke scale can establish cognitive function after stroke. Cerebrovasc Dis. 2010;30(1):7–14. https://doi.org/10.1159/000313438.CrossRefPubMed

Title: Soluble ST2 and risk of cognitive impairment after acute ischemic stroke: a prospective observational study
Authors: Yinwei Zhu
Chongquan Fang
Qi Zhang
Yaling Lu
Rui Zhang
Aili Wang
Xiaoqing Bu
Jintao Zhang
Zhong Ju
Yonghong Zhang
Tan Xu
Chongke Zhong
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Stroke
Published in: BMC Geriatrics / Issue 1/2021
Electronic ISSN: 1471-2318
DOI: https://doi.org/10.1186/s12877-021-02288-6

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Soluble ST2 and risk of cognitive impairment after acute ischemic stroke: a prospective observational study

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Frailty related all-cause mortality or hospital readmission among adults aged 65 and older with stage-B heart failure inpatients

Exploring life-space in the nursing home. An observational longitudinal study

Sleep duration and incident frailty: The Rural Frailty Study

Functional decline in hospitalized older patients with coronavirus disease 2019: a retrospective cohort study

Higher prevalence of geriatric depression, catastrophizing pain and sleep disorders in institutionalized elders: a cross-sectional study in Galle District, Sri Lanka

Perspectives of older adults with a chronic condition on functioning, social participation and health: a qualitative study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page